Trials / Completed
CompletedNCT03556098
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Steno Diabetes Center Copenhagen · Academic / Other
- Sex
- Male
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
In the present project the investigators will evaluate whether glucagonotropic properties of the gut-derived incretin hormone glucose-dependent insulinotropic polypeptide (GIP) may be utilized as a safeguard against hypoglycemia in patients with T1D.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | glucose-dependent insulinotropic peptide | Infusion of GIP |
| DRUG | Glucose-Dependent Insulin-Releasing Hormone[3-30] | Infusion of GIP antagonist GIP\[3-30\] |
| DRUG | Saline Solution | Infusion of Saline |
Timeline
- Start date
- 2019-02-22
- Primary completion
- 2020-02-11
- Completion
- 2020-02-11
- First posted
- 2018-06-14
- Last updated
- 2021-05-10
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03556098. Inclusion in this directory is not an endorsement.